Certolizumab pegol for the treatment of psoriasis

References

• Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):677–698.
   PubMed Web of Science ®Google Scholar
• Yost J, Gudjonsson JE. The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. F1000 Med Rep. 2009;8:1.
   Google Scholar
• Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: so far, so near. World J Hepatol. 2015 Mar 27;7(3):315–326.
   PubMed Web of Science ®Google Scholar
• Giannoni M, Consales V, Campanati A, et al. Homocysteine plasma levels in psoriasis patients: our experience and review of the literature. J Eur Acad Dermatol Venereol. 2015;29(9):1781–1785.
   PubMed Web of Science ®Google Scholar
• Campanati A, Ganzetti G, Di Sario A, et al. Insulin resistance, serum insulin and HOMA-R. J Gastroenterol. 2013;48:673.
   PubMed Web of Science ®Google Scholar
• Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007;20(4):731–736.
   PubMed Web of Science ®Google Scholar
• Campanati A, Molinelli E, Ganzetti G, et al. The effect of low-carbohydrates calorie-restricted diet on visceral adipose tissue and metabolic status in psoriasis patients receiving TNF-alpha inhibitors: results of an open label controlled, prospective, clinical study. J Dermatolog Treat. 2016;23:1–7.
   Google Scholar
• Campanati A, Ganzetti G, Giuliodori K, et al. Biologic therapy in psoriasis: safety profile. Curr Drug Saf. 2016;11(1):4–11.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174.
   PubMed Web of Science ®Google Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris – update 2015 – short version – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29:2277–2294.
   PubMed Web of Science ®Google Scholar
• Boyd, T, Kavanaugh A. Novel approaches to biological therapy for psoriatic arthritis. Expert Opin Biol Ther. 2016;16(2):173–186.
   PubMed Web of Science ®Google Scholar
• Campanati A, Goteri G, Simonetti O, et al. CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept. Br J Dermatol. 2007;157(6):1155–1160.
   PubMed Web of Science ®Google Scholar
• Campanati A, Moroncini G, Ganzetti G, et al. Adalimumab modulates angiogenesis in psoriatic skin. Eur J Inflamm. 2013;11(2):489–498.
   Web of Science ®Google Scholar
• Cimzia (certolizumab pegol): prescribing information [Internet]. Silver Spring (MA): Food and Drug Administration. 2016. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf
   Google Scholar
• Cimzia (certolizumab pegol): summary of product characteristics [Internet]. London (UK): European Medicine Agency. 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf
   Google Scholar
• Cimzia (certolizumab pegol): prescribing information [Internet]. Bruxelles (BE): UCB. 2016. Available from: https://www.cimzia.com/assets/pdf/Prescribing_Information.pdf
   Google Scholar
• Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014;28(Suppl 1):S15–S23.
   PubMed Web of Science ®Google Scholar
• Ueda N, Tsukamoto H, Mitoma H, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor alpha. Inflamm Bowel Dis. 2013;19(6):1224–1231.
   PubMed Web of Science ®Google Scholar
• UCB Biopharma S.P.R.L.; Dermira, Inc. An efficacy and safety study of two dose levels of certolizumab pegol (CZP) in subjects with plaque psoriasis (PSO) (CIMPASI-1). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US. Available from https://clinicaltrials.gov/show/NCT02326298 Identifier: NCT02326298
   Google Scholar
• UCB Biopharma S.P.R.L.; Dermira, Inc. A study to evaluate the efficacy and safety of two dose levels of certolizumab pegol (CZP) in subjects with plaque psoriasis (PSO) (CIMPASI-2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US. Available from https://clinicaltrials.gov/show/NCT02326272 Identifier: NCT02326272
   Google Scholar
• UCB Biopharma S.P.R.L.; Dermira, Inc. Efficacy and safety study of certolizumab pegol (CZP) versus active comparator and placebo in subjects with plaque psoriasis (PSO) (CIMPACT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US. Available from https://clinicaltrials.gov/show/NCT02346240 Identifier: NCT02346240
   Google Scholar
• Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180–190.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55.
   PubMed Web of Science ®Google Scholar
• Mease P, Deodhar A, Fleischmann R, et al. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open. 2015;25;1(1):e000119.
   Google Scholar
• Gladman D, Fleischmann R, Coteur G, et al. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken). 2014;66(7):1085–1092.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Gladman D, Van Der Heijde D, et al. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomized placebo-controlled study. Ann Rheum Dis. 2015;74(1):44–51.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11–12):1318–1327.
   PubMed Web of Science ®Google Scholar
• Barthel C, Biedermann L, Frei P, et al. Induction or exacerbation of psoriasis in patients with Crohn’s disease under treatment with anti-TNF antibodies. Digestion. 2014;89(3):209–215.
   PubMed Web of Science ®Google Scholar
• Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. 
Br J Dermatol. 2010;162:780–785.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.
   PubMed Web of Science ®Google Scholar
• Garceˆs S, Emengeot J, Benito-Garcia E, et al. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947–1955.
   PubMed Web of Science ®Google Scholar
• De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13(12):1673–1682.
   PubMed Web of Science ®Google Scholar
• Thomas SS, Nabeel N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. Syst Rev Meta-Analysis Biodrugs. 2015;29(4):241–258.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65:1213–1223.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Mcinnes CT, Iain B, et al. Maintenance of efficacy and safety of ustekinumab in patients with active psoriatic arthritis despite prior conventional nonbiologic and anti-TNF biologic therapy: 1 yr results of the PSUMMIT 2 trial. Ann Rheum Dis. 2013;72:A48–A.
   Web of Science ®Google Scholar